Frova(R) Meets Primary Endpoint In Second Phase III Study For Prevention Of Menstrual Migraine (Medical News Today)
Vernalis plc (LSE: VER, Nasdaq: VNLS) and Endo Pharmaceuticals HoldingsInc. (Nasdaq: ENDP) today announced top-line data from the second Phase IIIefficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for theshort-term (six-days per month) prevention of menstrual migraine (MM). Thedata from this study corroborate the positive findings in a prior efficacystudy published in Neurology in

State HC asks Vascular Concepts to take DCGI approval for selling DES in Maharashtra, directs FDA to stay away (PharmaBiz)
The Mumbai High Court has directed state Food and Drugs Administration (FDA) to stay away from the dispute with the Bangalore-based Vascular Concepts over the sale of medical devices in Maharashtra, as the Central Government has already come out with the regulatory guidelines for the same.

Intradyn Upgrades App (Byte and Switch)
ST. PAUL, Minn. -- Intradyn (www.intradyn.com), the leader in simple, affordable solutions for automated email compliance, announced today it has released a major update to the software of its email archiving appliance for small to midsized businesses (SMBs).